MiNK Therapeutics (INKT) Assets Average (2021 - 2026)
MiNK Therapeutics (INKT) posted Assets Average of $12.3 million for Q1 2026, down 15.71% sequentially from $14.6 million in Q4 2025, and up 146.45% YoY from $5.0 million in Q1 2025.
MiNK Therapeutics (INKT) Assets Average (2021 - 2026) Analysis & Trends
MiNK Therapeutics has reported Assets Average for 6 years, with the latest figure at $12.3 million in Q1 2026.
- Quarterly Assets Average rose 146.45% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 146.45% YoY) and the FY2025 annual result came in at $10.0 million, up 94.29% from the prior year.
- Assets Average eased to $12.3 million in Q1 2026 per INKT's latest filing, from $14.6 million in the prior quarter.
- Over five years, Assets Average peaked at $38.2 million in Q1 2022 and troughed at $3.4 million in Q2 2025.
- A 5-year average of $14.5 million and a median of $9.8 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2026: Assets Average tumbled 74.29% in 2023, then surged 146.45% in 2026.
- Over 5 years, Assets Average stood at $23.4 million in 2022, then sank by 74.29% to $6.0 million in 2023, then grew by 9.0% to $6.5 million in 2024, then jumped by 123.0% to $14.6 million in 2025, then slipped by 15.71% to $12.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $12.3 million, $14.6 million, and $8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | 10.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.00 Mn |
| Mar 31, 2026 | 12.31 Mn |
| Dec 31, 2025 | 14.60 Mn |
| Sep 30, 2025 | 8.72 Mn |
| Jun 30, 2025 | 3.38 Mn |
| Mar 31, 2025 | 4.99 Mn |
| Dec 31, 2024 | 6.55 Mn |
| Sep 30, 2024 | 8.85 Mn |
| Jun 30, 2024 | 8.61 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Dec 31, 2023 | 6.01 Mn |
| Sep 30, 2023 | 9.79 Mn |
| Jun 30, 2023 | 14.35 Mn |
| Mar 31, 2023 | 19.03 Mn |
| Dec 31, 2022 | 23.37 Mn |
| Sep 30, 2022 | 28.19 Mn |
| Jun 30, 2022 | 33.63 Mn |
| Mar 31, 2022 | 38.19 Mn |
| Dec 31, 2021 | 22.16 Mn |